ATAI adds MD­MA biotech to grow­ing list of psy­che­del­ic mak­ers; Aca­dia adds $52.5M up­front pain buy­out

For years, the biggest push in psy­che­del­ic drug de­vel­op­ment has been around MD­MA, a par­ty drug long thought to have po­ten­tial ben­e­fits for pa­tients with PTSD. Rick Doblin, for years psy­che­del­ic ther­a­py’s most promi­nent ad­vo­cate and fundrais­er, and his non-prof­it, MAPS, have raised mil­lions to ad­vance clin­i­cal tri­als, most re­cent­ly rais­ing $30 mil­lion to com­plete a Phase III study in vet­er­ans.

But ATAI, the Ger­man-born biotech that has quick­ly be­come the most promi­nent pri­vate pro­mot­er and dri­ver of psy­che­del­ic ther­a­py, still thinks they have some­thing to of­fer. Yes­ter­day, the port­fo­lio an­nounced their lat­est sub­sidiary: Em­path­Bio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER